— -- A bone-building drug also may help certain women with early breast cancer, a study shows. Breast cancer patients who took the drug Zometa, in addition to hormonal therapy, were 35% less ...

November 1, 2011 — In postmenopausal breast cancer patients, bisphosphonates are commonly used to counter the adverse effects of aromatase inhibitors (AIs) on bone. Now there is a suggestion that the ...

NEW YORK, Dec 9 (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in ...

Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss ...

SAN ANTONIO - Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast-cancer treatment. Seven years later, they ...

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and ...

August 22, 2008 — Concomitant zoledronic acid (Zometa, Novartis) that is given during adjuvant endocrine therapy can prevent bone loss in premenopausal breast cancer patients. It also improves ...

Methods We examined the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

LONDON, Nov 20 (Reuters) - Novartis AG has withdrawn its application to extend the use of its bone drug Zometa in Europe, the European Medicines Agency said on Wednesday. Zometa, which was first ...